Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon5 and 330 bp insertion in exon5.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-NMI, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
N myc interactor often referred to as NMI interacts with members of the MYC family including N-MYC and C-MYC. Known as N-MYC and C-MYC interacting protein NMI has a molecular weight of approximately 54 kDa. NMI expresses in a variety of tissues with higher levels in brain and liver tissues. Its presence is also notable in immune cells pointing towards a complex role in cellular processes related to both developmental and immune responses.
Biological function summary
NMI collaborates with transcription factors to influence the regulation of gene expression. It plays a significant role in the formation of protein complexes that regulate transcriptional activities of oncogenes particularly through interaction with MYC and STAT proteins. NMI's ability to form complexes makes it a notable player in modulating signal transduction pathways. Its balancing act with transcription factors affects cell proliferation and differentiation critical components of its biological functionality.
Pathways
NMI has a significant impact on the JAK-STAT signaling pathway and the MYC-mediated transcription network. Within these pathways NMI modulates the activities of the MYC family of oncogenes and interacts with signal transducers and activators like STATs. These interactions contribute to the regulation of cellular processes such as growth and apoptosis. Such pathways illustrate NMI's role in maintaining cellular homeostasis and its interactive role with proteins like STAT and MYC.
NMI has been associated with cancer and autoimmune diseases. NMI's interaction with MYC oncogenes links it to various cancers particularly neuroblastoma. It also associates with autoimmune disorder mechanisms implicating its expression and regulation in immune-related pathologies. In cancer NMI's relationship with MYC affects tumor growth and progression illustrating its potential as a target for therapeutic intervention. Its involvement highlights the importance of understanding its function in disease pathways.
